Pharmaceutical Companies Performance Tables 2010

Date: January 22, 2011
Pages: 438
Price:
US$ 865.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P7C1959FEECEN
Leaflet:

Download PDF Leaflet

Sample:

Download Free Sample

Pharmaceutical Companies Performance Tables 2010
In today’s challenging market, business planners and commercial management must ask themselves some key questions, such as...
  • Who are the winners and losers in terms of revenue growth?
  • Which companies have succeeded in maintaining or growing profits?
  • Overall R&D investment from the top 10 companies fell between 2008 and 2009 by US$421 million from US$57.54 billion to US$57.12 billion – yet some companies maintained or expanded R&D spend. Who were they?
  • Who are the fastest growers? 10 companies with joint 2005 sales of US$2.55 billion posted sales of $US13.06 billion in 2009. Who were they?
  • Which companies are cash rich or cash poor?

Pharmaceutical Company Performance Tables

The answers to thousands of key questions are in the new 2010 edition

This essential fully-updated business reference report compares and contrasts the performance and fortunes of leading pharmaceutical companies and places them in easy-to-read tables. Importantly, in addition to rankings, the new edition of the report includes the individual results for 162 companies and up to five years of key data from the balance sheet, income statement and cash flow.

Key Facts & Benefits of this report:
  • Full 2009 year-end figures
  • Contains a wide range of detailed performance rankings for more than 160 leading pharmaceutical companies
  • Includes individual company results
  • Provides up to five years of trend data
  • Available in print or pdf with web access included free of charge!

Trends affecting the global industry

The challenging economic environment continues to affect health spending in many countries which has impacted the pharmaceutical industry’s commercial performance. Issues which are affecting companies’ performance, include...
  • The number of blockbuster drugs which have lost patent protection, and the number is set to rise over the coming years, have not been replaced by new products offering significant therapeutic advances
  • Those products which have been launched – increasingly in the biological area – have attracted criticism and objection from health payers due to their high cost
  • Many companies continue to post rising revenues and increasing profits, although for many it is against a background of cost cutting
  • Mergers and acquisitions, and especially technology/product acquisition, have taken an increasing role in market entry/expansion plans
  • Generic competition continues to erode the profits of off-patent products, although spending constraints and rising competition are creating pressure in the generic sector.

Pharmaceutical Companies Performance Tables

A unique opportunity to assess companies’ financial and operating performances.

Use it for...

Competitor analysis
Acquisition targeting
Partnering and licensing background
PR and Marketing
Performance benchmarking

Just some of the 162 companies in the 2010 edition...

Abbott Laboratories
Abraxis BioScience
Ajinomoto
Alcon Laboratories
Allergan
Amgen
Amylin Pharmaceuticals
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
BTG International
Celgene
Chugai
CSL Limited
Cubist Pharmaceuticals
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dendreon
Dr Reddy’s Labs
Egis
Eisai
Elan
Eli Lilly
Endo Pharmaceuticals
Enzon Pharmaceuticals
Eurand
Forest Laboratories
Gedeon Richter
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Human Genome Sciences
ImmunoGen
Incyte
Inspire Pharmaceuticals
Ipsen
Isis Pharmaceuticals
Johnson & Johnson
KRKA
Kyowa Kirin
Lundbeck
Mannkind
Merck & Co
Merck KGaA
Mitsubishi Tanabe Pharma
Mylan Laboratories
Nipro
Novartis
Novo Nordisk
NPS Pharmaceuticals
Nycomed
Ono Pharmaceuticals
Orion
OSI Pharmaceuticals
Otsuka
Pfizer
Procter & Gamble
Ranbaxy
Recordati
Regeneron Pharmaceuticals
Roche
sanofi-aventis
Sawai
Shionogi
Shire Pharmaceuticals
Stada Arzneimittel
Takeda
Teva Pharmaceutical Industries
Theravance
UCB
Vertex Pharmaceuticals
XOMA
ZymoGenetics

Extensive Contents

Key Financial Indicators include:
Pharmaceutical Sales
Total Revenues
Cost of Sales
Operating Income
Net Income
Earnings per Share
R&D Expenditure
Capital Expenditure
Return on Capital Employed
Total Assets
Cash in Hand
Employees
Companies are also ranked by:
Productivity
Profitability
Research Rates
Investment Rates

Performance Indicators:

(Using Pharmaceutical Sales as an example)
Companies by Pharmaceutical Sales 2005-2009 (US$m)
Companies by Yearly Change (Local Currency)
Companies by Five-Year Change (Local Currency)
Five-Year Movement of Pharmaceutical Sales
(2000 constant US$ Exchange Rates)
Five-Year Change in Pharmaceutical Sales
(Index Numbers)
PHARMACEUTICAL COMPANIES PERFORMANCE TABLES 2010 PART 1

INTRODUCTION

PHARMACEUTICAL SALES

Absolute Pharma Revenues (US$ millions YER)
Absolute Pharma Revenues (US$ millions CER)
1 Year Percentage Change in Pharma Revenue (Local Currencies)
1 Year Absolute Change in Pharma Revenue (US$ millions CER)
5 Year Absolute Change in Pharma Revenue (US$ millions CER)
5 Year Percentage Change in Pharma Revenue (Local Currencies)
Pharmaceutical Revenues by Company Location 2005-2009 - Japan, Asia & Rest of the World
Pharmaceutical Revenues by Company Location 2005-2009 - Europe
Pharmaceutical Revenues by Company Location 2005-2009 - United States
Pharmaceutical Revenues by Company Location 2005-2009 - Regional Comparisons

REVENUES

Absolute Consolidated Revenue (US$ millions YER)
Absolute Consolidated Revenue (US$ millions CER)
1 Year Percentage Change in Consolidated Revenue (Local Currencies)
5 Year Percentage Change in Consolidated Revenue (Local Currencies)
5 Year Absolute Change in Consolidated Revenue (US$ millions CER)
1 Year Absolute Change in Consolidated Revenue (US$ millions CER)

NET PROFITS

Absolute Net Profits (US$ millions YER)
Absolute Net Profits (US$ millions CER)
Absolute Net Profitability %

GROSS PROFITS

Absolute Gross Profits (US$ millions YER)
Absolute Gross Profits (US$ millions CER)

UNDERLYING PROFITS

Absolute Underlying Profits (US$ millions YER)
Absolute Underlying Profits (US$ millions CER)
Absolute Underlying Profitability %

OPERATING PROFITS

Absolute Operating Profits (US$ millions YER)
Absolute Operating Profits (US$ millions CER)
Absolute Operating Profitability %

OPERATING PROFIT PRODUCTIVITY

Absolute Operating Profit Productivity (US$ millions YER)
Absolute Operating Profit Productivity (US$ millions CER)
1 Year Absolute Change in Operating Profit Productivity (US$ millions CER)
5 Year Absolute Change in Operating Profit Productivity (US$ millions CER)

NET PROFIT PRODUCTIVITY

Absolute Net Profit Productivity (US$ millions YER)
Absolute Net Profit Productivity (US$ millions CER)
1 Year Absolute Change in Net Profit Productivity (US$ millions CER)
5 Year Absolute Change in Net Profit Productivity (US$ millions CER)

CASH FLOWS

Absolute Net Cash Flows (US$ millions YER)
Absolute Net Cash Flows (US$ millions CER)
Absolute Operating Cash Flows (US$ millions YER)
Absolute Operating Cash Flows (US$ millions CER)
5 Year Absolute Change in Operating Cash Flows (US$ millions CER)
1 Year Absolute Change in Operating Cash Flows (US$ millions CER)
Absolute Financing Cash Flows (US$ millions YER)
Absolute Financing Cash Flows (US$ millions CER)
Absolute Investing Cash Flows (US$ millions YER)
Absolute Investing Cash Flows (US$ millions CER)
Absolute Cash in Hand (US$ millions YER)
Absolute Cash in Hand (US$ millions CER)
5 Year Absolute Change in Cash in Hand (US$ millions CER)
1 Year Absolute Change in Cash in Hand (US$ millions CER)
5 Year Percentage Change in Cash in Hand (Local Currencies)
Percentage Change in Cash in Hand (Local Currencies)
Summation of Cash in Hand (US$ millions CER)
Percentage Liquidity against Total Assets
Percentage Liquidity against Consolidated Revenue

R&D EXPENDITURE

Absolute R&D Expenditure (US$ millions YER)
Absolute R&D Expenditure (US$ millions CER)
1 Year Absolute Change in R&D Expenditure (US$ millions CER)
5 Year Absolute Change in R&D Expenditure (US$ millions CER)
5 Year Percentage Change in R&D Expenditure (Local Currencies)
1 Year Percentage Change in R&D Expenditure (Local Currencies)
Absolute Research Rate

SG&A EXPENSES

Absolute SG&A Expenses (US$ millions YER)
Absolute SG&A Expenses (US$ millions CER)
1 Year Absolute Change in SG&A Expenses (US$ millions CER)
5 Year Percentage Change in SG&A Expenses (Local Currencies)
1 Year Percentage Change in SG&A Expenses (Local Currencies)
Absolute SG&A Rate

CAPITAL EXPENDITURE

Absolute Capital Expenditure (US$ millions YER)
Absolute Capital Expenditure (US$ millions CER)
1 Year Absolute Change in Capital Expenditure (US$ millions CER)
5 Year Absolute Change in Capital Expenditure (US$ millions CER)
5 Year Percentage Change in Capital Expenditure (Local Currencies, Million)
1 Year Percentage Change in Capital Expenditure (Local Currencies, Million)
Summation of Capital Expenditures (US$ millions CER)

TOTAL LIABILITIES

Absolute Long Term Liabilities (US$ millions YER)
Absolute Long Term Liabilities (US$ millions CER)
1 Year Absolute Change in Total Liabilities (US$ millions CER)
5 Year Absolute Change in Total Liabilities (US$ millions CER)
1 Year Percentage Change in Total Liabilities (Local Currencies)
5 Year Percentage Change in Total Liabilities (Local Currencies)

LONG TERM LIABILITIES

Absolute Long Term Liabilities (US$ millions YER)
Absolute Long Term Liabilities (US$ millions CER)
1 Year Absolute Change in Long Term Liabilities (US$ millions CER)
5 Year Absolute Change in Long Term Liabilities (US$ millions CER)
1 Year Percentage Change in Long Term Liabilities (Local Currencies)
5 Year Percentage Change in Long Term Liabilities (Local Currencies)

ASSETS

Absolute Current Assets (US$ millions YER)
Absolute Current Assets (US$ millions CER)
1 Year Absolute Change in Current Assets (US$ millions CER)
5 Year Absolute Change in Current Assets (US$ millions CER)
5 Year Percentage Change in Current Assets (Local Currencies)
1 Year Percentage Change in Current Assets (Local Currencies)

TOTAL ASSETS

Absolute Total Assets (US$ millions YER)
Absolute Total Assets (US$ millions CER)
5 Year Absolute Change in Total Assets (US$ millions CER)
1 Year Absolute Change in Total Assets (US$ millions CER)
5 Year Percentage Change in Total Assets (Local Currencies)
1 Year Percentage Change in Total Assets (Local Currencies)

TANGIBLE ASSETS

Absolute Tangible Assets (US$ millions YER)
Absolute Tangible Assets (US$ millions CER)
5 Year Absolute Change in Tangible Assets (US$ millions CER)
1 Year Absolute Change in Tangible Assets (US$ millions CER)
Percentage Change in Tangible Assets (Local Currencies)
5 Year Percentage Change in Tangible Assets (Local Currencies)

INTANGIBLE AND OTHER ASSETS

Absolute Intangible and Other Assets (US$ millions YER)
Absolute Intangible and Other Assets (US$ millions CER)
5 Year Absolute Change in Intangible and Other Assets (US$ millions CER)
5 Year Absolute Change in Intangible and Other Assets (US$ millions CER)
1 Year Percentage Change in Intangible and Other Assets (Local Currencies)
5 Year Percentage Change in Intangible and Other Assets (Local Currencies)

ASSETS PER EMPLOYEE

Absolute Total Assets per Employee (US$ millions YER)
Absolute Total Assets per Employee (US$ millions CER)
1 Year Absolute Change in Total Assets per Employee (US$ millions CER)
5 Year Absolute Change in Total Assets per Employee (US$ millions CER)
1 Year Percentage Change in Total Assets per Employee (Local Currencies)
5 Year Percentage Change in Total Assets per Employee (Local Currencies)

EMPLOYEES

Absolute Employees
5 Year Absolute Change in Employees
1 Year Absolute Change in Employees
5 Year Percentage Change in Employees
1 Year Percentage Change in Employees

TOTAL COSTS

Absolute Total Costs (US$ millions YER)
Absolute Total Costs (US$ millions CER)
5 Year Absolute Change in Total Costs (US$ millions CER)
1 Year Absolute Change in Total Costs (US$ millions CER)
5 Year Percentage Change in Total Costs (US$ millions LC)
1 Year Percentage Change in Total Costs (Local Currency)

CURRENT LIABILITIES

Absolute Current Liabilities (US$ millions YER)
Absolute Current Liabilities (US$ millions CER)
5 Year Absolute Change in Current Liabilities (US$ millions CER)
1 Year Absolute Change in Current Liabilities (US$ millions CER)
5 Year Percentage Change in Current Liabilities (Local Currencies)
1 Year Percentage Change in Current Liabilities (Local Currencies)

COST OF SALES

Absolute Cost of Sales (US$ millions YER)
Absolute Cost of Sales (US$ millions CER)
5 Year Absolute Change in Cost of Sales (US$ millions CER)
1 Year Absolute Change in Cost of Sales (US$ millions CER)
5 Year Percentage Change in Cost of Sales (Local Currencies)
1 Year Percentage Change in Cost of Sales (Local Currencies)

PRODUCTIVITY

Absolute Revenue Productivity (US$ YER)
Absolute Revenue Productivity (US$ CER)
1 Year Absolute Change in Revenue Productivity (US$ CER)
5 Year Absolute Change in Revenue Productivity (US$ CER)
5 Year Percentage Change in Revenue Productivity (US$ CER)
1 Year Percentage Change in Revenue Productivity (US$ CER)

SHAREHOLDERS EQUITY

Absolute Shareholders Equity (US$ millions YER)
Absolute Shareholders Equity (US$ millions CER)
1 Year Absolute Change in Shareholders Equity (US$ millions CER)
5 Year Absolute Change in Shareholders Equity (US$ millions CER)

INVESTMENT RATES

Percentage Investment Rate against Tangible Assets
Percentage Investment Rate against Total Assets

CURRENT RATIOS

Absolute Current Ratios
5 Year Absolute Change in Current Ratios
1 Year Absolute Change in Current Ratios
Gearing %

PHARMACEUTICAL COMPANIES PERFORMANCE TABLES 2010 PART 2

COMPANY RESULTS

Abbott Laboratories
Abraxis Bioscience
Affymax
Ajinomoto
Alcon Laboratories
Alexion Pharmaceuticals
Alkermes
Allergan
Allos Therapeutics
Alnylam Pharmaceuticals
American Oriental Bioengineering
Amgen
Amicus Therapeutics
Amylin Pharmaceuticals
Angiotech
Arena Pharmaceuticals
Asahi Kasei
Astellas
Astra Zeneca
Axcan Pharma
Baxter International
Bayer
Biogen Idec
Biomarin Pharmaceuticals
Biotest
Biovail
Boehringer Ingleheim
Bristol-Myers Squibb
BTG International
Cadence Pharmaceuticals
Cangene
Caraco Pharmaceutical Laboratories
Celgene
Cephalon
Cerus
Chugai
Columbia Laboratories
Crucell
CSL Limited
Cubist Pharmaceuticals
Cypress Bioscience
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dendreon
Discovery Laboratories
Dr Reddys
Durect
Dyax
Egis
Eisai
Elan
Eli Lilly
Emergent Biosolution
Endo Pharmaceuticals
Enzon Pharmaceuticals
Eurand
Evotek
Exelixis
Forest Laboratories
Gedeon Richter
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
GTx
Human Genome Sciences
Idenix
Idera
Incyte
Immunogen
Inspire Pharmaceuticals
Intermune
Ipsen
Isis Pharmaceuticals
Johnson and Johnson
King Pharmaceuticals
Kissei Pharmaceutical
KRKA
Kyowa Hakko Kirin
Lexicon Pharmaceuticals
Ligand Pharmaceuticals
Lundbeck
Mannkind
MAP Pharmaceuticals
Martek Biosciences
Medicis Pharmaceutical
Merck & Co
Merck KGaA
Micromet
Mitsubishi Tanabe Pharma
Molecular Insight
Momenta
Nabi Biopharmaceuticals
Nektar Therapeutics
Neurocrine Biosciences
Nippon Shinyaku
Nipro
Novartis
Novo Nordisk
NPS Pharmaceuticals
Nycomed
Ono Pharmaceuticals
Onyx Pharmaceuticals
Optimer Pharmaceuticals
Orexigen Therapeutics
Orion
OSI Pharmaceuticals
Osiris Therapeutics
Otsuka
Pain Therapeutics
Paladin Labs
Palatin Technologies
Par Pharmaceutical Companies
Pfizer
Pharmasset
Pharmaxis
Poniard Pharmaceuticals
Procter and Gamble
Progenics
QLT
Questcor
Ranbaxy
Recordati
Regeneron
Repligen
Rigel Pharmaceuticals
Roche
Salix Pharmaceuticals
sanofi-aventis
Santen Pharmaceutical
Savient Pharmaceuticals
Sawai
Sciclone
Seattle Genetics
Seikagaku
Shionogi
Shire Pharmaceuticals
Simcere Pharmaceutical
Stada Arzneimittel
Sucampo Pharmaceuticals
Sumitomo Chemical
Supergen
Taisho Pharmaceutical
Takeda Chemical Industries
Teijin
Teva Pharmaceutical Industries
The Medicines Company
Theravance
Trimeris
UCB
United Therapeutics
Valeant Pharmaceuticals
Vectura
Vertex Pharmaceuticals
ViroPharma
Vivus
Warner Chilcott
Watson Pharmaceuticals
XenoPort
Xoma
ZymoGenetics

METHODOLOGY

Absolute Ranking
Absolute Change
Percentage Change
Currencies
  Dollar Exchange Rates 2005 – 2009
  Dollar Index Rates 2005 – 2009
Accounting Measures
Skip to top


Ask Your Question

Pharmaceutical Companies Performance Tables 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: